In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Product Liability Litigation

383 F. App'x 242
Court of Appeals for the Third Circuit·Decided June 7, 2010·No. 09-3818·Unpublished·Cited by 16 cases

Opinion

OPINION OF THE COURT

VAN ANTWERPEN, Circuit Judge.

Appellants are thirty-six class members of the Diet Drugs multidistrict litigation (“Bridgewater petitioners”) represented by Joseph Simon. They appeal the order of the United States District Court for the Eastern District of Pennsylvania denying as untimely a motion for reconsideration or modification of pretrial order (“PTO”) 7763A. Appellees, Class Counsel, 1 (“Class Counsel”) assert that the District Court did not abuse its discretion in denying the motion as untimely. We agree with Class Counsel and will affirm the District Court’s order.

I.

Because we write solely for the parties, we will address only those facts necessary to our opinion.

This appeal arises out of the In re Diet Drugs Product Liability Litigation, a multidistrict, nationwide product liability class action against the drug manufacturer Wyeth. 2 The District Court certified a class on August 26, 1999 to pursue claims against Wyeth for the manufacture and *244 distribution of Pondimin and Redux, two appetite suppressants, after researchers discovered an association between taking the appetite suppressants and developing valvular heart disease (“VHD”) and pulmonary hypertension (“PPH”). We have recounted the background of this case several times and will not recount it again now. See In Re Diet Drugs Prods. Liab. Litig., 582 F.3d 524, 529-37 (3d Cir.2009); In re Diet Drugs Prods. Liab. Litig., 385 F.3d 386, 389-91 (3d Cir.2004); In re Diet Drugs Prods. Liab. Litig., 282 F.3d 220, 225-29 (3d Cir.2002).

Relevant to this appeal is PTO 7763A, the order in which the District Court distributed the final fee award to attorneys who worked for the common benefit of the class. The fee award compensated attorneys for work done related to the class action and for their future work pursuant to administering the Settlement Trust 3 until it closes in 2015. The District Court invited any interested parties to submit a memorandum and attend a hearing on how to determine and distribute the final attorneys’ fee award. Ninety law firms claimed entitlement to common benefit funds. After the hearing, an auditor submitted a report of the compensable time and expenses claimed by counsel, and informed the court that from the inception of the litigation Class Counsel expended 553,-020.53 hours working for the common benefit of the class, producing a lodestar of $156,849,247.24.

On July 16, 2007, Class Counsel and the Plaintiffs Management Committee (“PMC”) 4 submitted a joint-petition for a final fee award. In it, the joint-fee petitioners noted that the Settlement Trust had paid out over $300 million in benefits per year to the class since it started making payments in 2001. Specifically, it noted that the Settlement Trust paid out $240 million in benefits in 2005 and 2006, and estimated,

it appears clear that even if the Trust pays out Matrix benefits 5 at half the annual rate that has prevailed since the Trial Court approved the [Settlement Agreement] during the remaining five years in which most Class Members retain their eligibility for High Level Matrix benefits, substantially all the ~ $732 million that currently remains of the original Settlement Fund will be exhausted.

(App.206-07.) The joint-fee petitioners also speculated that, if claims continued to be filed against the trust at the current rate of $240 million a year, the class members would receive a benefit that is greater than the total value of the Settlement Trust. 6 Because the joint-fee petitioners estimated *245 that the entire Settlement Trust would be exhausted, they requested an award based on the total amount in the Settlement Trust.

On April 8, 2008, the District Court ruled on the joint-fee petition for a final award in PTO 7763A, the focal point of this appeal. The court valued the Settlement Agreement at approximately $6.44 billion. It noted that, at the time the joint-fee petitioners filed their claim, $732 million remained available in the Settlement Trust, and it estimated “based upon that average amount of Matrix Benefits the Trust has paid per year ... [,] that is, approximately $240,000 per year,” that the Settlement Trust would be exhausted. In re Diet Drugs Prods. Liab. Litig., 553 F.Supp.2d 442, 469 n. 47 (E.D.Pa.2008). Assuming that the Settlement Trust would be exhausted, the District Court applied percentage-of-recovery analysis to the entire $6.44 billion to determine the fee award for counsel. It concluded an award equal to 6.75% of the recoveries was fair and appropriate, and awarded the joint-petitioners $434,511,711.22 in fees. On July 21, 2008, the District Court entered PTOs allocating the aggregate fee awards among the ninety joint-fee applications, and certified the award as final. Two appeals followed. Because no one sought a stay of the fee award, the award was distributed.

On April 8, 2009, the Bridgewater petitioners filed a motion to reconsider or modify the fee award ordered in PTO 7763A under Federal Rule of Civil Procedure 60(b) pursuant to subsections (1), (2), (3), and (6). In the motion, the Bridgewa-ter petitioners did not explain why they waited one year to file the motion. They did, however, argue the fee award was excessive. The claimants noted that the monthly trust reports indicated that the Settlement Trust only paid out $69,980,000 in benefits in 2007, and $53,722,117 for 2008, far below the estimated $240 million annual pay-out. Based on this information, they contend there is a trend toward diminishing pay-outs and speculated that there will be between $400 and 500 million remaining in the Settlement Trust when it closes. Therefore, they assert that the firm of Levin, Fishbein, Sedran & Berman should not have collect advanced attorneys’ fees on these funds because they may never benefit the class. 7 In response, Class Counsel offered an unopposed declaration from Warren Bruck Bilkner, Ph.D., a bio-statistician who, after studying the Matrix payments, concluded that there “is no reasonable basis to conclude that the monthly payments data of the Trust for the period of January, 2007 through March, 2009 demonstrates a trend toward decreasing Matrix payments over time.” (App.9.)

Free access — add to your briefcase to read the full text and ask questions with AI

In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Product Liability Litigation, 383 F. App'x 242 (3d Cir. 2010).

383 F. App'x 242 (In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Product Liability Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related